01511nam2-2200445---450-99000329143020331620090717104019.0978-2-503-52793-2000329143USA01000329143(ALEPH)000329143USA0100032914320090708d2009----km-y0itay50------bafreFR||||||||001yyThesaurus Zosimihistoria novacurantibus Bastien Kindt, Françoise Van Haeperen et CENTALTurnhoutBrepols2009XIX, 304 p.33 cm12 micofichesCorpus christianorum. Thesaurus patrum graecorumSulla cop. : Universitas Catholica Lovaniensis, Lovani Novi2001Corpus christianorum. Thesaurus patrum graecorum20010010003291322001Corpus christianorum. Thesaurus patrum graecorumZosimoHistoria novaConcordanzeBNCF888.02Zosimus391820SOMERS,VeroniqueKINDT,BastienCentre de traitement automatique du langageITsalbcISBD990003291430203316V.4. Coll. 14/ 4210441 LMV.4. Coll.00164137BKUMASENATORE9020090708USA011046SENATORE9020090716USA011023SENATORE9020090717USA011040Thesaurus Zosimi1117830UNISA05307nam 2201705z- 450 991055738540332120210501(CKB)5400000000042045(oapen)https://directory.doabooks.org/handle/20.500.12854/68583(oapen)doab68583(EXLCZ)99540000000004204520202105d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierAdvances in Multiple Sclerosis Research-Series IBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 online resource (334 p.)3-03943-947-2 3-03943-948-0 Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue focused on delivery methods to be used for vaccines, immunotherapeutic approaches, drug design, and anti-inflammatories and their outcomes in preclinical studies and clinical trials.Medicinebicsscadult-onsetagonist peptidealemtuzumabaltered peptide ligandsantibodies against GluR3 peptideantibody detectionantigen-specific immunotherapiesantigen-specific immunotherapyastrocytesautoimmune diseasesautoimmune encephalitisautoimmunityB cell receptorbiomarkerbupropioncarrierscellular immunitycentral nervous systemcerebral blood flowchloroquineclinical outcomeclinical outcomesclinical phenotypecognitive impairmentconformational analysisconjugationcranial nerve-VI palsycraniopharyngiomadelivery methodsdendritic cellsdiagnosisdiagnostic markersdisease-modifying treatmentsdrug delivery nanosystemsEAEearly-onsetELISAexperimental autoimmune encephalomyelitisfampridinefractionated stereotactic radiation treatmentsfree light chainsGraphite/SiO2 electrodegut microbiomegut-brain axisHPLCHuman Leucocyte Antigensimmune modulationimmune thrombocytopenic purpuraimmunogeneticsimmunoglobulinsimmunomodulationimmunotherapeuticsimmunotherapyinflammationintracortical facilitationkappalipidsmajor depressionmannanMBP83-99 peptidememory T cellsmetagenomicsmicrogliaMOG35-55molecular dynamicmonoclonal antibodiesMSMS drugsmultiple sclerosisMultiple Sclerosismultivalencymyelin basic proteimyelin oligodendrocyte glycoproteinmyelin peptidesN-glucosylated peptide epitopesnanoparticlesnanotechnologyneurodegenerationneuroimagingneuropsychological assessmentNMR spectroscopyNOE-constraintsoligodendrocytesoxidativepeptidepeptidesplasma exchangepolymerspositron emission tomographyprobioticsproteolipid proteinS-adenosylmethioninesample sizeshort intracortical inhibitionsphenoid sinusitisST285Streptococcus thermophilusT cell receptortDCStetraspaninstherapeuticstolerancetolerance inductiontolerogenic vaccinestrimolecular complexTSPAN32vaccinevaccinesvitamin D3voltammetrywalking disabilityyogaMedicineMatsoukas J(John)edt1309053Apostolopoulos VassoedtMatsoukas J(John)othApostolopoulos VassoothBOOK9910557385403321Advances in Multiple Sclerosis Research-Series I3029272UNINA